 |
|
STAT3 Gene Regulates Cancer Stem Cells in Brain Cancer
August 10, 2009In a study published online in advance of print in Stem Cells, Tufts researchers report that the STAT3 gene regulates cancer stem cells in brain cancer. Cancer stem cells have many characteristics of stem cells and are thought to be the cells that drive tumor formation. The researchers report that STAT3 could become a target for cancer therapy, specifically in Glioblastoma multiforme (GBM), a type of malignant and aggressive brain tumor.
Patients with Glioblastoma multiforme typically survive 12 to 14 months with treatment. Treatment options include radiation, chemotherapy, and surgery.
"When STAT3 is inhibited, cancer stem cells in glioblastomas lose their stem-cell characteristics permanently, suggesting that STAT3 regulates growth and self-renewal of stem cells within glioblastomas. Strikingly, a single, acute treatment with STAT3 inhibitors was effective, implying that a STAT3 inhibitor could stop tumor formation," said senior author Brent Cochran, PhD, a professor at Tufts University School of Medicine and a member of the cellular & molecular physiology program faculty at the Sackler School of Biomedical Sciences at Tufts.
"STAT3 has been shown to be activated in a number of human tumors. This study is one of the first to show, however, that STAT3 regulates cancer stem cells. It is one of the few genes linked to the propagation of cancer stem cells, and it appears to regulate processes involved in the six hallmarks of cancer: growth, metastasis, angiogenesis, evasion of apoptosis, tissue invasion, and cell immortalization," he continued.
The researchers used cancer stem cells isolated from surgically removed samples of glioblastoma tumors. Cell cultures were treated with two chemically distinct small-molecule inhibitors (STA-21 and S3I-201) of STAT3. After several days of treatment, cell growth in the STAT3-inhibited cultures was minimal compared to growth in the control cultures. Moreover, in the STAT-inhibited cultures, proteins that help maintain stem-cell characteristics were apparently turned off. This finding leads the researchers to believe that STAT3 has a distinct role to play in cancer stem cells, which may make it an especially good target for cancer therapy.
"Current cancer therapies that prolong life do not specifically target cancer stem cells, and these cells are often resistant to traditional radiation and chemotherapies. STAT3 appears to govern the propagation of cancer stem cells in Glioblastoma multiforme. Targeted inhibition of STAT3 in GBM cancer stem cells gives us a new approach to treating this devastating brain cancer," said Julian Wu, MD, associate chairman of neurosurgery and chief of the division of neurosurgical oncology at Tufts Medical Center. He is also a professor at Tufts University School of Medicine. Dr. Wu is known for his expertise in gene therapy for brain tumors and the molecular genetics of primary and metastatic brain tumors.
"We are encouraged by the potential of STAT3 in our study," said Cochran. "Research has already demonstrated that STAT3 and cancer go hand in hand, but, until this study, we did not know that STAT3 regulates cancer stem cells, which are extremely resistant to conventional therapy. Given these findings, I hope that our future research investigating the mechanisms involved in inhibiting STAT3 will contribute to more effective and less invasive cancer therapies."
First author Maureen Sherry is a graduate student in cellular & molecular physiology at the Sackler School and is a member of Cochran's laboratory.
This study was supported by the Brain Tumor Society (now the National Brain Tumor Society) and by a training grant from the National Institutes of Health.
Sherry MM, Reeves A, Wu JK, and Cochran BH. 2009. Stem Cells. "STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells." Published online August 5, 2009, doi: 10.1002/stem.185
About Tufts University School of Medicine
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. The Sackler School undertakes research that is consistently rated among the highest in the nation for its impact on the advancement of medical science.
Tufts University School of Medicine
"STAT3 has been shown to be activated in a number of human tumors. This study is one of the first to show, however, that STAT3 regulates cancer stem cells. It is one of the few genes linked to the propagation of cancer stem cells, and it appears to regulate processes involved in the six hallmarks of cancer: growth, metastasis, angiogenesis, evasion of apoptosis, tissue invasion, and cell immortalization," he continued.
The researchers used cancer stem cells isolated from surgically removed samples of glioblastoma tumors. Cell cultures were treated with two chemically distinct small-molecule inhibitors (STA-21 and S3I-201) of STAT3. After several days of treatment, cell growth in the STAT3-inhibited cultures was minimal compared to growth in the control cultures. Moreover, in the STAT-inhibited cultures, proteins that help maintain stem-cell characteristics were apparently turned off. This finding leads the researchers to believe that STAT3 has a distinct role to play in cancer stem cells, which may make it an especially good target for cancer therapy.
"Current cancer therapies that prolong life do not specifically target cancer stem cells, and these cells are often resistant to traditional radiation and chemotherapies. STAT3 appears to govern the propagation of cancer stem cells in Glioblastoma multiforme. Targeted inhibition of STAT3 in GBM cancer stem cells gives us a new approach to treating this devastating brain cancer," said Julian Wu, MD, associate chairman of neurosurgery and chief of the division of neurosurgical oncology at Tufts Medical Center. He is also a professor at Tufts University School of Medicine. Dr. Wu is known for his expertise in gene therapy for brain tumors and the molecular genetics of primary and metastatic brain tumors.
"We are encouraged by the potential of STAT3 in our study," said Cochran. "Research has already demonstrated that STAT3 and cancer go hand in hand, but, until this study, we did not know that STAT3 regulates cancer stem cells, which are extremely resistant to conventional therapy. Given these findings, I hope that our future research investigating the mechanisms involved in inhibiting STAT3 will contribute to more effective and less invasive cancer therapies."
First author Maureen Sherry is a graduate student in cellular & molecular physiology at the Sackler School and is a member of Cochran's laboratory.
This study was supported by the Brain Tumor Society (now the National Brain Tumor Society) and by a training grant from the National Institutes of Health.
Sherry MM, Reeves A, Wu JK, and Cochran BH. 2009. Stem Cells. "STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells." Published online August 5, 2009, doi: 10.1002/stem.185
About Tufts University School of Medicine
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. The Sackler School undertakes research that is consistently rated among the highest in the nation for its impact on the advancement of medical science.
Tufts University School of Medicine
Cancer Stem Cells Current Events and Cancer Stem Cells News RSSGovernor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
MDC scientists show how hematopoietic stem cell development is regulated
During cell division, whether hematopoietic stem cells (HSCs) will develop into new stem cells (self-renewal) or differentiate into other blood cells depends on a chemical process called DNA methylation.
Echoes of phlogiston in stem cell biology
Before it was learned that matter burns by taking up oxygen, most chemists sought to explain combustion as the release of a mysterious substance, which they named "phlogiston".
Penn State College of Medicine research isolates liver cancer stem cells prior to tumor formation
Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.
Diabetes drug kills cancer stem cells in combination treatment in mice
In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers reported in the September 14 online first edition of Cancer Research, a journal of the American Association for Cancer Research.
Turning back the clock: Fasting prolongs reproductive life span
Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone.
First compound that specifically kills cancer stem cells found
The cancer stem cells that drive tumor growth and resist chemotherapies and radiation treatments that kill other cancer cells aren't invincible after all.
Stripping leukemia-initiating cells of their 'invisibility cloak'
Two new studies reveal a way to increase the body's appetite for gobbling up the cancer stem cells responsible for acute myeloid leukemia (AML), a form of cancer with a particularly poor survival rate.
Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia
Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.
Neural stem cell differentiation factor discovered
Neural stem cells represent the cellular backup of our brain. These cells are capable of self-renewal to form new stem cells or differentiate into neurons, astrocytes or oligodendrocytes.
More Cancer Stem Cells Current Events and Cancer Stem Cells News Articles
 |
Cancer Stem Cells: Methods and Protocols (Methods in Molecular Biology) by John S. Yu (Editor) Through the revolutionary concept of cancer stem cells, cancer research has been reinvigorated to study the role of these unique cells in cancer propagation and as targets of innovative therapies. In Cancer Stem Cells: Methods and Protocols, preeminent researchers have compiled cancer stem cell research techniques and protocols to promote healthy competition, discourse, and collaboration in this vital field. The volume covers extensive topics such as identification and isolation of cancer stem cells, animal models of cancer stem cells, methylation profiling, the contribution of the niche in the regulation of cancer stem cells, immunologic targeting, and the use of normal stem cells as a treatment, among other subjects. Written in the highly successful Methods in Molecular Biology™... |
 |
Cancer Stem Cells: Identification and Targets by Sharmila A. Bapat (Editor) Because the concept and discoveries of cancer stem cells are relatively new, scientists and researchers need an introduction to this dynamic area. Cancer Stem Cells presents a consolidated account of the research done to date and recent progresses in the studies of cancer stem cells. Such a presentation facilitates a better understanding of and draws attention to stem cell and cancer biology - two fields that enhance, move, and evolve into each other continuously. It provides an informative study in designing approaches to apply stem cell principles to cancer biology while offering an overview of the challenges in developing combination stem and cancer biology targets for therapeutics. This book serves as a primer for new researchers in the field of cancer biology. |
 |
Cancer Stem Cells by William L. Farrar PhD (Editor) A remarkable paradigm shift has occurred in recent years regarding the biological origins of cancer. The cancer stem cell hypothesis has challenged the foundational notions of cancer, and the therapeutic implications have been profound. Compelling evidence indicates that errors in the development of a small subset of adult stem cells can lead to cancer. Only this small sub-population of cells has the inherent ability to form tumors and metastasize. This book discusses the emerging field of cancer stem cell research, with contributions from leading experts on the basic biology, genetic pathways, and potentials for therapeutic targeting of cancer stem cells. It also covers clinical challenges for these new discoveries, namely, that cancer stem cells might be resistant to conventional... |
 |
Charlie Rose - Stem Cells / Cancer Treatments / Reggie Jackson and Bob Gibson (October 1, 2009) A discussion about stem cells with Lasker Award winners Shinya Yamanaka and John Gurdon || A discussion about Cancer Treatments with Lasker Award winners Brian Druker, Nicholas Lydon and Charles Sawyers || Reggie Jackson and Bob Gibson discuss baseball and their book "Sixty Feet, Six Inches: A Hall of Fame Pitcher and A Hall of Fame Hitter Talk about How the Game Is Played" This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Stem Cells and Cancer by Sadhan Majumder (Editor) Cancer is a primary cause of human mortality worldwide. Despite decades of basic and clinical research, the outcome for most cancer patients is still dismal. Some stumbling blocks to developing effective therapy include the heterogeneity of cancer tissues, the lack of knowledge about the critical molecular mechanisms in cancer tissues (which are typically aberrant compared with mechanisms in normal tissue), and the lack of good mechanism-based therapeutic approaches. The recent findings that most cancers contain a small fraction of self-renewing, differentiation-blocked stem cell-like cells (cancer stem cells) and that it is these cells—and not the major bulk of the tissue—that are the root cause for cancer initiation and metastasis have also highlighted the need to change our... |
|
Hematopoiesis by Alexey Bersenev Analytical reviews and discussions about stem cell research, cell therapy, regenerative medicine, immunology, leukemia researchKindle blogs are fully downloaded onto your Kindle so you can read them even when you're not wirelessly connected. And unlike RSS readers which often only provide headlines, blogs on Kindle give you full text content and images, and are updated wirelessly throughout the day. | |
 |
Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) by O.D. Wiestler (Editor), B. Haendler (Editor), D. Mumberg (Editor) Cancer stem cells have originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth and differentiation pathways responsible for cancer stem cell proliferation and survival will help in the discovery identification of novel therapeutic targets. Developing selective drugs against cancer stem cells offers great therapeutic opportunities but also provides for major challenges regarding preclinical models, therapeutic windows, and clinical study end points. |
 |
Cancer Stem Cells: the Origin of Cancer Directed By: Karen Sutton Also With: Karen Sutton (Producer) Cancer stem cells are the key to how cancer originates and the key to successful therapy. This lecture will address what cancer stem cells are, how they maintain themselves, and why they may be resistant to some current treatments. Dr. Weissman will also This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Autologous And Cancer Stem Cell Gene Therapy (Progress in Gene Therapy) by Roger Bertolotti (Author), Keiya Ozawa (Author), Roger Bertolotti (Editor), Keiya Ozawa (Editor) Stem cells provide for life-long cell replacement in tissues and organs, and have inherent homing abilities that are critical in therapeutic applications. Stem cells are also the driving force of cancer where genetic/epigenetic alterations culminate in tumorigenesis either in tissue stem cells or in some of their derivatives. As a rare subset of the tumor, cancer stem cells are the only drive of tumor initiation/propagation. Autologous and cancer stem cells are thus the key targets of 1) long-term and transient-regenerative/epigenetic gene therapy and 2) of recurrence-free anticancer therapy, respectively. While cancer stem cell gene therapy still needs time to accomplish, autologous stem cells have been instrumental in the first unequivocal successes for gene therapy whereby ex vivo... |
 |
Cancer Stem Cells: Webster's Timeline History, 1990 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Cancer Stem Cells," including when used in literature (e.g. all authors that might have Cancer Stem Cells in their name). As such, this book represents the largest compilation of timeline events associated with Cancer Stem Cells when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the... |
| © 2009 BrightSurf.com |